Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EBT (2016 - 2025)

Historic EBT for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $22.8 million.

  • Mimedx's EBT rose 10009.63% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.7 million, marking a year-over-year decrease of 707.17%. This contributed to the annual value of $57.3 million for FY2024, which is 8703.36% up from last year.
  • Per Mimedx's latest filing, its EBT stood at $22.8 million for Q3 2025, which was up 10009.63% from $13.0 million recorded in Q2 2025.
  • In the past 5 years, Mimedx's EBT ranged from a high of $23.2 million in Q2 2024 and a low of -$10.8 million during Q2 2022
  • Moreover, its 5-year median value for EBT was $9.2 million (2023), whereas its average is $5.3 million.
  • The largest annual percentage gain for Mimedx's EBT in the last 5 years was 1073296.7% (2022), contrasted with its biggest fall of 50571.75% (2022).
  • Mimedx's EBT (Quarter) stood at $91000.0 in 2021, then surged by 10732.97% to $9.9 million in 2022, then surged by 41.13% to $13.9 million in 2023, then decreased by 19.15% to $11.2 million in 2024, then skyrocketed by 103.12% to $22.8 million in 2025.
  • Its EBT was $22.8 million in Q3 2025, compared to $13.0 million in Q2 2025 and $8.6 million in Q1 2025.